NeuroOne Medical Technologies (Nasdaq:NMTC) announced today that it received a patent for drug delivery with neural probe devices.
The United States Patent and Trademark Office (USPTO) issued the patent titled “Agent-Delivering Neural Probe Devices and Related Systems and Methods.” It covers novel electrodes that can operate as a standard neural electrode that delivers a treatment agent to a target area of the brain.
A step into the drug delivery space would mark further progress for NeuroOne, which develops thin-film electrode technologies.
The company already has a patent portfolio that includes both neural and spinal cord electrodes. Their unique structures optimize the functionality and minimized profile of those electrodes.
Get the full story at our sister site, Drug Delivery Business News.